Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 342 followers
Latest posts
Last updated 2 minutes ago
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
2 minutes ago
Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights...
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
about 1 hour ago
About a year after halving its staff in a clinical push, Arsenal...
Medtronic recalls reflux monitoring device as 184 serious injuries linked to capsule
about 1 hour ago
Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid risks...
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
about 1 hour ago
A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary...
Novocure hit by cyberattack exposing patient data
about 2 hours ago
Novocure has become the latest medtech company to be hit by a...
Boston Scientific halts sales of angiographic catheters amid ‘two serious injuries’
about 2 hours ago
Boston Scientific has told its customers to stop using its Imager II...
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
about 5 hours ago
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune...
Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events
about 17 hours ago
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune...
Natera teams with Angiex on cancer drug trial monitoring
about 19 hours ago
Natera inked a collaboration deal with biotech Angiex to assess the use...
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
about 23 hours ago
The 2026 IPO streak continues as Electra Therapeutics has filed to go...
‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
about 24 hours ago
As the hype around the vast medical potential of GLP-1 drugs continues...
ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial
about 24 hours ago
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart...